Market Overview

Pneumothorax is a condition of collapsed lung in which air from lung enters into the outer space of chest wall. Pneumothorax often is result of various lung diseases such as chronic obstructive pulmonary disease (COPD), cystic fibrosis, lung cancer, asthma, tuberculosis, bacterial pneumonia, emphysema, etc. Various triggering factors are identified in pneumothorax such as family history, smoking, etc.

The symptoms of the pneumothorax are often mild at start and are difficult to be noticed hence it makes the diagnosis difficult. Symptoms such as shortness of breath, chest pain, fatigue, rapid breathing or rapid heartbeat are observed in potential diagnosis of the pneumothorax. As per World Health Organization (WHO), over 251 million worldwide cases of COPD are reported in 2016 with mortality of over 3.1 million in one year.

Increasing prevalence of respiratory diseases such as COPD, asthma, etc. is expected to drive the growth of the pneumothorax infection treatment market. Increasing aging population across the world makes it people prone to the respiratory diseases further expected to drive the growth of the pneumothorax infection treatment market.

Availability of effective treatment for the pneumothorax across different regions further expected to fuel the growth of the pneumothorax infection treatment market. Increasing early diagnosis of pneumothorax due to comparatively increasing awareness about the various respiratory diseases is expected to drive the growth of the pneumothorax infection treatment market.

Rapidly increasing advanced therapies for the management of pneumothorax in developed as well as developing countries expected to bring additional traction in pneumothorax infection treatment market growth. Increasing prevalence of diseases such as cystic fibrosis, cancer, etc. which are prevalent in countries such as China, the United States and European countries which are high revenue generating region further expected to drive the growth of the pneumothorax infection treatment market.

Improving state of healthcare in various developing countries such India, Brazil, etc. increases the chances of diagnosis of chronic diseases which in turn expected to drive the growth of the pneumothorax infection treatment market.

Whereas, delayed diagnosis and low rate of diagnosis of pneumothorax may hampers the potential growth prospect of the pneumothorax infection treatment market. Limited awareness about the pneumothorax infections in underdeveloped countries as well as developing countries may limit the growth of the pneumothorax infection treatment market.

FREE Report Sample is Available

In-depth report coverage is now just a few seconds away

Get FREE Report Sample

Market Segmentation

By treatment type	Pleurectomy Bullectomy Pleurodesis Others
By indication	Primary spontaneous pneumothorax Infection Secondary spontaneous pneumothorax Infection Injury-related pneumothorax Infection Tension pneumothorax Infection Others
By end user	Hospitals Ambulatory Surgery Centers Specialty Clinics

Make This Report Your Own

Take Advantage of Intelligence Tailored to your Business Objective

Get a Customized Version

Regional Outlook

By region, the global pneumothorax infection treatment market is expected to be dominated by North America due to higher prevalence of the pneumothorax infection in the region. Europe is expected to be the second most lucrative region in the global pneumothorax infection treatment market.

Latin America is expected to experience steady growth in global pneumothorax infection treatment market. Asia-Pacific pneumothorax infection treatment market is expected to be fastest growing market whereas MEA is pneumothorax infection treatment market is expected to be least lucrative.